356 related articles for article (PubMed ID: 31654368)
1. Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology.
Solans BP; Garrido MJ; Trocóniz IF
Clin Pharmacokinet; 2020 Feb; 59(2):123-135. PubMed ID: 31654368
[TBL] [Abstract][Full Text] [Related]
2. Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.
Buil-Bruna N; López-Picazo JM; Martín-Algarra S; Trocóniz IF
Oncologist; 2016 Feb; 21(2):220-32. PubMed ID: 26668254
[TBL] [Abstract][Full Text] [Related]
3. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.
Rousseau A; Marquet P
Fundam Clin Pharmacol; 2002 Aug; 16(4):253-62. PubMed ID: 12570013
[TBL] [Abstract][Full Text] [Related]
4. Practical treatment guide for dose individualisation in cancer chemotherapy.
Canal P; Chatelut E; Guichard S
Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
[TBL] [Abstract][Full Text] [Related]
5. Adaptive control methods for the dose individualisation of anticancer agents.
Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
[TBL] [Abstract][Full Text] [Related]
6. Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review.
Saeheng T; Na-Bangchang K; Karbwang J
Eur J Clin Pharmacol; 2018 Nov; 74(11):1365-1376. PubMed ID: 29978293
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.
Zandvliet AS; Schellens JH; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2008; 47(8):487-513. PubMed ID: 18611060
[TBL] [Abstract][Full Text] [Related]
8. Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.
Bullock JM; Lin T; Bilic S
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S105-S115. PubMed ID: 28921642
[TBL] [Abstract][Full Text] [Related]
9. Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.
Zhou L; Higashimori M; Shen K; Zhang Z; Sheng J; Xu H; Horiuchi M; Ichikawa K; Al-Huniti N; Zhou D
Clin Pharmacol Ther; 2019 Jun; 105(6):1303-1320. PubMed ID: 30802932
[No Abstract] [Full Text] [Related]
10. Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development.
Zhu P; Sy SKB; Skerjanec A
AAPS J; 2018 Mar; 20(2):40. PubMed ID: 29516330
[TBL] [Abstract][Full Text] [Related]
11. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
[TBL] [Abstract][Full Text] [Related]
12. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.
Lee JY; Garnett CE; Gobburu JV; Bhattaram VA; Brar S; Earp JC; Jadhav PR; Krudys K; Lesko LJ; Li F; Liu J; Madabushi R; Marathe A; Mehrotra N; Tornoe C; Wang Y; Zhu H
Clin Pharmacokinet; 2011 Oct; 50(10):627-35. PubMed ID: 21895036
[TBL] [Abstract][Full Text] [Related]
13. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
[TBL] [Abstract][Full Text] [Related]
14. Accelerating anticancer drug development - opportunities and trade-offs.
Nass SJ; Rothenberg ML; Pentz R; Hricak H; Abernethy A; Anderson K; Gee AW; Harvey RD; Piantadosi S; Bertagnolli MM; Schrag D; Schilsky RL
Nat Rev Clin Oncol; 2018 Dec; 15(12):777-786. PubMed ID: 30275514
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology.
Rodallec A; Benzekry S; Lacarelle B; Ciccolini J; Fanciullino R
Crit Rev Oncol Hematol; 2018 Sep; 129():1-12. PubMed ID: 30097227
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.
Bender BC; Schindler E; Friberg LE
Br J Clin Pharmacol; 2015 Jan; 79(1):56-71. PubMed ID: 24134068
[TBL] [Abstract][Full Text] [Related]
17. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study.
Adamson PC; Widemann BC; Reaman GH; Seibel NL; Murphy RF; Gillespie AF; Balis FM
Clin Cancer Res; 2001 Oct; 7(10):3034-9. PubMed ID: 11595692
[TBL] [Abstract][Full Text] [Related]
19. A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology.
Park K
Yonsei Med J; 2017 Jan; 58(1):1-8. PubMed ID: 27873489
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring in cancer--are we missing a trick?
Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
